Welcome to our dedicated page for VIVEVE MEDICAL news (Ticker: VIVE), a resource for investors and traders seeking the latest updates and insights on VIVEVE MEDICAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VIVEVE MEDICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VIVEVE MEDICAL's position in the market.
Viveve Medical reported Q2 2022 revenue of $1.8 million, a slight increase from $1.7 million in Q2 2021. The company sold 14 Viveve Systems and 2,850 disposable treatment tips, raising the total installed base to 905 systems globally. Gross profit was $0.3 million (16% of revenue), up from $0.2 million (10%). However, net loss increased to $7.1 million or ($0.67) per share, compared to $5.2 million or ($0.49) per share in the prior year. Cash reserves decreased to $9.4 million from $19.2 million at year-end.
Viveve Medical (NASDAQ:VIVE) will report its second quarter 2022 financial results and provide a corporate update on August 11, 2022, after U.S. market close. A conference call is scheduled for 5:00 PM ET, accessible via phone or live webcast. Viveve specializes in women's health, particularly in treating stress urinary incontinence (SUI) with its Viveve® System, cleared by the FDA for various surgical procedures. The company's ongoing clinical trial, PURSUIT, aims to improve SUI outcomes, with topline results expected by the end of 2022.
Viveve Medical, Inc. (NASDAQ:VIVE) announced the issuance of Taiwan Patent No. I766557 for its dual-energy technology, enhancing its intellectual property in a significant Asian market. CEO Scott Durbin emphasized the importance of this patent for Viveve's global clinical development and commercialization strategies, particularly for treating stress urinary incontinence (SUI) in women. The Viveve System is already approved for various surgical procedures in Taiwan, with distribution managed by Dynamic Medical Technologies.
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ: VIVE) announces CEO Scott Durbin's participation in the H.C. Wainwright Global Investment Conference from May 23 - 26, 2022. The conference will include a corporate presentation and meetings with investors, with the presentation scheduled for May 24, 2022, at 7:00 AM ET. The event will be broadcast on Viveve's investor website and archived for 90 days. Viveve focuses on women's health and is advancing clinical trials for stress urinary incontinence (SUI), with expected results by the end of 2022.
Viveve Medical reported $1.6 million in total revenue for Q1 2022, a slight increase from $1.5 million in Q1 2021. The company sold approximately 2,750 consumable treatment tips and added 11 Viveve Systems, bringing the global total to 895 systems.
Net loss for the quarter was $7.2 million, or ($0.67) per share. Operating expenses rose to $5.8 million, up from $5.5 million in the previous year. As of March 31, 2022, cash and cash equivalents totaled $14.0 million.
Viveve Medical (NASDAQ: VIVE) will report its Q1 2022 financial results and provide a corporate update on May 12, 2022, after U.S. markets close. A conference call will follow at 5:00 PM ET, accessible via phone or webcast. The company is recognized for its innovative solutions in women's intimate health, including the FDA-cleared Viveve System. The ongoing PURSUIT trial for stress urinary incontinence is critical, with topline results expected by the end of 2022, potentially supporting new indications in the U.S.
Viveve Medical reported total revenue of $6.4 million for 2021, reflecting a 17% year-over-year growth. The company completed enrollment in the pivotal PURSUIT trial for stress urinary incontinence (SUI) and is currently conducting 12-month follow-up visits. Gross profit increased to $0.6 million (10% of revenue), up from $0.3 million (5% of revenue) in 2020. However, the net loss widened to approximately $26.7 million, with cash and equivalents at $19.2 million as of year-end 2021. A conference call will provide further updates.
Viveve Medical (NASDAQ:VIVE) will release its full year 2021 financial results and corporate update on March 17, 2022.
The conference call starts at 5:00 PM ET, accessible via phone or live webcast. Viveve, focused on women's intimate health, utilizes Cryogen-cooled Monopolar Radiofrequency technology for its Viveve® System, which has received FDA clearance for general surgical use.
The company is also advancing its clinical program for stress urinary incontinence (SUI), with topline results from the PURSUIT trial expected at the end of 2022.
Viveve Medical announced that its Senior VP, Suzon Lommel, has been recognized as one of The Top 25 Women Leaders in Medical Devices for 2022 by The Healthcare Technology Report, marking her second consecutive year on this list. Under her leadership, Viveve is advancing its technology to treat stress urinary incontinence (SUI)clinical program for SUI, with top-line results from its ongoing PURSUIT trial expected in late 2022, which could support a new SUI indication in the U.S.
FAQ
What is the current stock price of VIVEVE MEDICAL (VIVE)?
What is the market cap of VIVEVE MEDICAL (VIVE)?
